MAP BioPharma
Case Study

MAP’s vision to accelerate patient access to medicines, devices and diagnostics is at the heart of everything we do.

Case study 1:

Supporting our client with a successful submission to NICE’s Highly Specialised Technology (HST) programme


  •  Our client had developed an innovative treatment for patients with an ultra-rare condition, affecting fewer than ten patients per 100,000 of the population. There were no existing treatment alternatives.

  •  NICE’s HST programme is designed to address some of the challenges facing such treatments, including limited data and potential uncertainty around outcomes.

  •  However, not all treatments for ultra-rare conditions can be considered through the HST programme and there is no guarantee of success for those that are admitted.


  •  MAP has worked on over 50% of all HST submissions. We were able to draw on this experience and the information contained in our market access portal, MAP Online, to ensure that our client was supported throughout the process.

  •  From practice scoping sessions to ensure that the client was fully prepared, to developing a compelling, robust submission, we managed to guide our client through each critical milestone of the process.


  •  Our client’s treatment was accepted onto the HST programme and was subsequently approved by NICE.

  •  Patients with a severe condition and previously unmet need were able to access this life-changing treatment through the NHS in England.

Case study-diagram
CareersTerms and ConditionsComplaints ProcedurePrivacy PolicyCookie Policy

Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.

MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom

 +44 (0) 1480 832360

MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281

VAT Group Registration Number:
GB 292 8576 52